• Research Technician II - Cancer Immunotherapy

    Job ID
    Regular Full-Time
    Fred Hutchinson Cancer Research Center
    Laboratory Research Sciences
  • Overview

    Cures Start Here. At Fred Hutchinson Cancer Research Center, home to three Nobel laureates, interdisciplinary teams of world-renowned scientists seek new and innovative ways to prevent, diagnose and treat cancer, HIV/AIDS and other life-threatening diseases. Fred Hutch’s pioneering work in bone marrow transplantation led to the development of immunotherapy, which harnesses the power of the immune system to treat cancer. An independent, nonprofit research institute based in Seattle, Fred Hutch houses the nation’s first cancer prevention research program, as well as the clinical coordinating center of the Women’s Health Initiative and the international headquarters of the HIV Vaccine Trials Network. Careers Start Here.

    The research technician is responsible for performing standard and investigative laboratory work in support of scientific research by performing bench-level experiments, operating analytical instruments, recovering, compiling and verifying the accuracy of research data; performing calculations; preparing charts, graphs and summaries.


    The Program in Immunology in the Clinical Research Division is looking for a highly motivated individual to support the development of genetically modified T cell immunotherapy for cancer. The successful candidate will utilize a variety of cutting-edge cellular and molecular techniques to analyze T cell immunity. The technician will work in the laboratory and be closely involved in the preclinical development of new T cell therapies and their translation into clinical trials. They should be capable of maintaining detailed laboratory records, analyzing data, managing supplies and reporting experimental results in a fast-paced environment.


    This position works under the direction of the Principal Investigator and senior laboratory personnel and will be involved in the following techniques/duties:

    • Tissue culture of mammalian cell lines and (patient-derived) primary human cells
    • Flow cytometry-based immunophenotyping, FACS isolation of mammalian cells
    • Lentiviral vector construction, modification, and viral transduction 
    • T-cell cytotoxicity assays, cytokine production and proliferation assays
    • Purification, cloning, and manipulation of genomic/plasmid DNA, cDNA, and RNA
    • PCR and RT-PCR, including Taqman quantitative assays
    • General laboratory duties and maintenance of laboratory equipment



    • A bachelor’s degree in a biological science
    • 2+ years of bench research experience 
    • Experience with mammalian cell culture and molecular biology techniques

    The candidate must be detail-oriented, a teamplayer and a fast and willing learner. The ideal candidate has prior experience with multicolor flow cytometry, FACS sorting and biological sample handling. Experience working with primary T cells and murine handling are highly desirable.

    Our Commitment to Diversity

    We are proud to be an Equal Employment Opportunity (EEO) and Vietnam Era Veterans Readjustment Assistance Act (VEVRAA) Employer. We are committed to cultivating a workplace in which diverse perspectives and experiences are welcomed and respected. We do not discriminate on the basis of race, color, religion, creed, ancestry, national origin, sex, age, disability (physical or mental), marital or veteran status, genetic information, sexual orientation, gender identity, political ideology, or membership in any other legally protected class. We are an Affirmative Action employer. We encourage individuals with diverse backgrounds to apply and desire priority referrals of protected veterans. If due to a disability you need assistance/and or a reasonable accommodation during the application or recruiting process, please send a request to our Employee Services Center at escmail@fredhutch.org or by calling 206-667-4700.


    Sorry the Share function is not working properly at this moment. Please refresh the page and try again later.
    Share on your newsfeed